Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection

• Published in: Journal of clinical microbiology Vol. 60; no. 3; p. e0224521
• Main Authors: Hernández-García, Marta, Castillo-Polo, Juan Antonio, Cordero, Desirèe Gijón, Pérez-Viso, Blanca, García-Castillo, María, Saez de la Fuente, Javier, Morosini, María Isabel, Cantón, Rafael, Ruiz-Garbajosa, Patricia
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 16-03-2022
• Subjects: Agar; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Azabicyclo Compounds; Bacterial Proteins - genetics; beta-Lactamases - genetics; Carbapenems - therapeutic use; Ceftazidime - pharmacology; Clinical Microbiology; Clone Cells; Drug Combinations; Epidemiology; Humans; Imipenem - therapeutic use; Klebsiella Infections - drug therapy; Klebsiella Infections - microbiology; Klebsiella pneumoniae - genetics; Meropenem; Microbial Sensitivity Tests; KPC-3-ST307-K. pneumoniae high-risk clone; carbapenemase phenotypic detection; novel blaKPC variants; ceftazidime-avibactam susceptibility
• ISSN: 0095-1137; 1098-660X
• DOI: 10.1128/jcm.02245-21

The emergence of Klebsiella pneumoniae isolates carrying novel
variants conferring ceftazidime-avibactam (CAZ/AVI) resistance is being increasingly reported. We evaluated the accuracy of phenotypic methods commonly used in routine clinical laboratories in the detection of novel K. pneumoniae carbapenemase (KPC) enzymes. Additionally, we characterized by whole-genome sequencing (WGS) the KPC-ST307-K. pneumoniae isolates recovered in our hospital before and after CAZ/AVI therapy. Rectal colonization or infection by carbapenem-resistant KPC-3 K. pneumoniae isolates (imipenem MIC, 16 mg/L; meropenem MIC, 8 to >16 mg/L) and CAZ/AVI-susceptible isolates (CAZ/AVI MIC, 1 to 2 mg/L) were first detected in three intensive care unit (ICU) patients admitted between March 2020 and July 2020. KPC K. pneumoniae isolates with increased CAZ/AVI MICs (8 to 32 mg/L) and carbapenem susceptibility (imipenem and meropenem MIC, <1 mg/L) were recovered within 6 to 24 days after CAZ/AVI treatment. WGS confirmed that all KPC K. pneumoniae isolates belonged to the sequence type 307 (ST307) high-risk clone and carried identical antimicrobial resistance genes and virulence factors. The presence of the novel
,
, and
genes was confirmed in the K. pneumoniae isolates with increased CAZ/AVI MICs and restored carbapenem activity. KPC production was confirmed by immunochromatography, the eazyplex Superbug CRE system, and the Xpert Carba-R assay in all KPC K. pneumoniae isolates, but not in any isolate using chromogenic agar plates for carbapenemase producers (ChromID-CARBA), the KPC/MBL/OXA-48 Confirm kit, and the β-CARBA test. Nevertheless, all grew in chromogenic agar plates for extended-spectrum β-lactamase (ESBL) producers (ChromID-ESBL). We report the failure of the most common phenotypic methods used for the detection of novel KPC carbapenemases but not of rapid molecular or immunochromatography assays, thus highlighting their relevance in microbiology laboratories.